Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis
Autore:
Beaujard, AC; Glehen, O; Caillot, JL; Francois, Y; Bienvenu, J; Panteix, G; Garbit, F; Grandclement, E; Vignal, J; Gilly, FN;
Indirizzi:
Ctr Hosp Lyon Sud, Dept Digest Surg, F-69495 Pierre Benite, France Ctr Hosp Lyon Sud Pierre Benite France F-69495 495 Pierre Benite, France Univ Lyon 1, Oncol Hyperthermia Lab, Oullins, France Univ Lyon 1 OullinsFrance n 1, Oncol Hyperthermia Lab, Oullins, France CHU Lyon Sud, Dept Intens Care, Lyon, France CHU Lyon Sud Lyon FranceCHU Lyon Sud, Dept Intens Care, Lyon, France CHU Lyon Sud, Dept Immunol, Lyon, France CHU Lyon Sud Lyon FranceCHU Lyon Sud, Dept Immunol, Lyon, France
Titolo Testata:
CANCER
fascicolo: 11, volume: 88, anno: 2000,
pagine: 2512 - 2519
SICI:
0008-543X(20000601)88:11<2512:ICWMCF>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
GASTRIC-CANCER; HYPERTHERMIC PERFUSION; CYTOREDUCTIVE SURGERY; CHEMOTHERAPY; CELLS; THERMOCHEMOTHERAPY; MORTALITY; TOXICITY; SURVIVAL;
Keywords:
peritoneal carcinomatosis; digestive tract cancer; intraperitoneal chemotherapy; hyperthermia; intracavitary hyperthermia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Gilly, FN Ctr Hosp Lyon Sud, Dept Digest Surg, F-69495 Pierre Benite, France Ctr Hosp Lyon Sud Pierre Benite France F-69495 Benite, France
Citazione:
A.C. Beaujard et al., "Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis", CANCER, 88(11), 2000, pp. 2512-2519

Abstract

BACKGROUND, Most patients with peritoneal carcinomatosis of digestive tract origin die within 6 months. Intraperitoneal chemohyperthermia (IPCH) associated with surgery has been reported as a possible new therapeutic approach. METHODS. A prospective Phase II trial was carried out with 83 patients whohad digestive tract cancer and peritoneal carcinomatosis to evaluate the tolerance and efficacy of IPCH with mitomycin C (MMC) associated with surgery. Eighty-six IPCH treatments with MMC were given as complementary therapy after surgery (peritoneal perfusate with a 10 mg/L dose of MMC; inflow temperature, 46-49 degrees C; use of a closed circuit; duration, 90 minutes). Primary tumors were mainly gastric (in 42 cases) or colorectal (in 27 cases). RESULTS. Mortality and morbidity occurred in 3 of 83 cases and 8 of 83 cases, respectively. For patients with resectable tumors, the median survival time was 16 months when carcinomatosis was Stage I and II (malignant granulations less than 5 mm in greatest dimension), whereas it was 6 months when carcinomatosis was Stage III and IV (malignant granulations more than 5 mm in greatest dimension). For patients with resectable gastric cancer and Stage I and II carcinomatosis, 1-, 2-, and 3-year actuarial survival rates were 80%, 61%, and 41%, respectively, whereas the rate was 10% at 1 year for patients with bulky disease (Stage III and IV),CONCLUSIONS: IPCH appears to be a promising new approach to treating patients with digestive tract cancers and peritoneal carcinomatosis with small, malignant granulations (Stage I and II). (C) 2000 American Cancer Society..

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 07:18:58